Company Overview of Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis, and human immunodeficiency virus (HIV-1). Its cenicriviroc product is an immunomodulator and dual inhibitor of CCR2 and CCR5 that is being evaluated for the treatment of non-alcoholic steatohepatitis, HIV-1, and others. The company was founded in 2006 and is based in South San Francisco, California.
701 Gateway boulevard
South San Francisco, CA 94080
Founded in 2006
Key Executives for Tobira Therapeutics, Inc.
Chief Medical Officer
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.
Tobira Therapeutics, Inc. Key Developments
Tobira Therapeutics Announces Initiation of ORION, a Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease
Aug 17 15
Tobira Therapeutics, Inc. announced the enrollment of the first patient into the Phase 2a ORION study. ORION is a randomized, double-blind, placebo-controlled study evaluating the treatment effects of cenicriviroc (CVC) in approximately 50 obese adults (BMI = 30 kg/m2) with prediabetes or diabetes and suspected non-alcoholic fatty liver disease (NAFLD). The primary outcome of ORION will measure changes in insulin sensitivity in peripheral and adipose tissue over a 24-week period and will include an interim analysis at 12 weeks. The over-expression of CCR2 and CCR5 receptors and their ligands in fat tissue of obese patients has been shown to promote inflammation and increase insulin resistance. Insulin resistance is associated with the development of NAFLD and is a key driver for disease progression to its more severe form, non-alcoholic steatohepatitis (NASH), as well as other diabetes related complications.
Tobira Therapeutics, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 11 15
Tobira Therapeutics, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations was $9,735,000 compared with $4,967,000 for the same period last year. Loss before income tax expense was $11,022,000 or $0.99 basic and diluted per share compared with $7,645,000 or $19.62 basic and diluted per share for the same period last year. Cash used in operations in the second quarter of 2015 was $9.8 million.
For the six months, the company reported loss from operations was $17,558,000 compared with $7,505,000 for the same period last year. Loss before income tax expense was $18,054,000 or $3.14 basic and diluted per share compared with $10,475,000 or $26.63 basic and diluted per share for the same period last year. Cash used in operations in the first six months of 2015 was $15.8 million.
Tobira Therapeutics, Inc. to Report Q2, 2015 Results on Aug 11, 2015
Aug 6 15
Tobira Therapeutics, Inc. announced that they will report Q2, 2015 results After-Market on Aug 11, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions